January 16, 2018 / 12:35 PM / a year ago

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

Jan 16 (Reuters) - Rxi Pharmaceuticals Corp:

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH

* RXI PHARMACEUTICALS CORP - COMPANY TO “CAPITALIZE” ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA)

* RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION

* RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below